Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Leukemia
•
Hematology
In a patient with tp53 mutated AML which has been refractory to Van+Aza and FLAG and in a center with limited clinical trial options; what treatment would you offer this patient?
Related Questions
Does the presence of asparaginase antibodies on Granger Genetics testing indicate need to switch asparaginase formulations?
What are your top takeaways in Hematologic Malignancies from ASCO 2023?
Do complex cytogenetics have any therapeutic or prognostic relevance in CLL?
Would you offer intensive CNS prophylaxis to Ph negative B-ALL patients who have possible mandibular nerve involvement on MRI face?
What is your approach to re-challenging BTK inhibitors for a patient who has had intolerance to several different agents?
Is it possible to give Inotuzumab ozogamicin in the front line setting for an older patient with Ph- Pre-B-ALL?
How would you manage an early isolated CNS relapse in a pediatric patient with Ph positive ALL?
What is the preferred approach for an AYA patient with VHR B-ALL with iAMP21 mutation with an isolated early CNS relapse?
Do you prefer to use 7+3 or CPX-351 as standard induction therapy in younger patients with AML-MRC or t-AML?
What is your current approach to maintenance therapy in FLT3-mutant AML post allogeneic HCT?
